An in vitro study by Wang et al. (21) conducted on different cell lines firstly demonstrated that tumor-derived IDH1R132C mutation sensitizes cells to ferroptosis, by reducing GPX4 levels through the production of the oncometabolite 2-hydroxyglutarate (2-HG). Here, GPX4 is linked to neoplasm.